AZN vs DRUG

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Apr 01, 2026

AZN

63.4
AI Score
VS
AZN Wins

DRUG

61.6
AI Score

Investment Advisor Scores

AZN

Apr 01, 2026
63score
Recommendation
BUY

DRUG

Apr 01, 2026
62score
Recommendation
BUY

AI Analyst Insights

Detailed Metrics Comparison

Metric AZN DRUG Winner
Forward P/E 17.5131 0 Tie
PEG Ratio 1.4974 0 Tie
Revenue Growth 4.1% 0.0% AZN
Earnings Growth 53.9% 0.0% AZN
Tradestie Score 63.4/100 61.6/100 AZN
Profit Margin 17.4% 0.0% AZN
Beta 1.00 1.00 Tie
Implied Volatility N/A N/A Tie
AI Recommendation BUY BUY Tie

Frequently Asked Questions

Based on our detailed analysis, AZN is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.